Navigation Links
Investor Call Scheduled to Discuss Ouster Proposal of Trinity Biotech Directors
Date:10/27/2008

KANSAS CITY, Mo., Oct. 27 /PRNewswire/ -- Thomas Reidy, an investor in Trinity Biotech plc (Nasdaq: TRIB), an Ireland-based developer and manufacturer of diagnostic products whose American Depository Receipts are traded on NASDAQ, will host an investor conference call November 3, 2008, at 10:00am EST, to discuss the recent shareholder proposal calling for the removal and replacement of Trinity Biotech's current directors.

On October 16, 2008, Mr. Reidy, and nine other shareholders, sent a letter to Trinity Biotech requesting that a special meeting of shareholders be held to consider the immediate removal of the current directors of Trinity Biotech. In the same letter, the investor group, who collectively hold beneficial ownership of more than 10% of Trinity Biotech's voting stock, directed that Trinity Biotech shareholders be given the opportunity to vote on the following slate of replacement directors:

-- Dr. Jack C. Chow, M.D., M.B.A. -- Partner, CRV Capital, LLC and adjunct

professor at Carnegie Mellon University's Heinz School of Public Policy

and Management;

-- Mr. Mike Gausling -- Managing Partner, Originate Ventures;

-- Dr. John H. Halsey, Ph.D. -- Chief Executive Officer, Director,

Founder, ProGene Biomedical, Inc. (dba IBT Laboratories);

-- Mr. Steven A. Mock, CPA -- Partner, BKD, LLP;

-- Mr. Thomas Reidy; and

-- Mr. Clint Severson -- Chairman, President and CEO of Abaxis, Inc.

According to Irish Law, Trinity Biotech must call a special meeting of shareholders, called an Extraordinary General Meeting, if the meeting is requested by shareholders holding in excess of 10% of the voting paid-up capital of the company.

The purpose of the conference call will be to provide Trinity Biotech shareholders information regarding the reasons for the proposal, the company's response to the proposal, if any, the qualifications of the replacement directors, and steps that shareholders can take to impose accountability on company management.

The conference call can be accessed in the U.S. by dialing 1-800-899-9949 conference code 2111155.

Thomas J. Reidy, Kansas City, (816) 260-8476


'/>"/>
SOURCE Thomas J. Reidy, Kansas City
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Nile Therapeutics to Present at the 7th Annual BIO Investor Forum
2. GenVault to Present at the BIOCOM Investor Conference
3. Neurobiological Technologies to Present at the BIO Investor Forum in San Francisco on October 30, 2008
4. China Medical Technologies Announces Reporting Dates for the September Quarter Results and Addresses Investor Inquiries
5. BioAtom Inc. To Present at BIOCOM Investor Conference 2008
6. Gerson Lehrman Group and BIO Collaborate to Identify Scientific Expertise for the Seventh Annual BIO Investor Forum
7. Oncothyreon to present at BIO Investor Forum 2008
8. Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
9. Celator(R) Pharmaceuticals To Present at 2008 BIO Investor Forum
10. Tobira Therapeutics, Inc. to Present at the 2008 BIO Investor Forum
11. WaferGen to Present at the Seventh Annual BIO Investor Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge ... envision new ways to harness living systems and biotechnology, ... Art (MoMA) in New York City ... 130 participating students, showcased projects at MoMA,s Celeste Bartos ... Paola Antonelli , MoMA,s senior curator of architecture and ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... Prairie, WI (PRWEB) , ... June 23, 2016 ... ... consultancy focused on quality, regulatory and technical consulting, provides a free webinar ... is presented on July 13, 2016 at 12pm CT at no charge. , ...
(Date:6/22/2016)... Research and Markets has announced the addition ... their offering. The global ... billion in 2013. The market is expected to grow at a ... 2020, increasing from $50.6 billion in 2015 to $96.6 billion in ... forecast period (2015 to 2020) are discussed. As well, new products ...
Breaking Biology Technology:
(Date:5/24/2016)... IRVINE, Calif. , May 24, 2016 Ampronix facilitates superior patient care ... LMD3251MT  3D medical LCD display is the latest premium product recently added to ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com , ... published the overview results from the Q1 wave of ... recent wave was consumers, receptivity to a program where ... with a health insurance company. "We were ... share," says Michael LaColla , CEO of Troubadour ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... of Infosys (NYSE: INFY ), and Samsung SDS, ... partnership that will provide end customers with a more ... payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) ... financial services, but it also plays a fundamental part in ...
Breaking Biology News(10 mins):